Clinical trials: Chronic Myeloid Leukemia (CML), open to volunteers
Hematologic Malignancy, Leukemia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT06131801
- Testing
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Myeloid Leukemia, CML
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A).
- Conditions
- Chronic Myeloid Leukemia, CML, CML, Chronic Phase
- Trial name
- POLARIS-2 (NCT06423911)
- Testing
- olverembatinib, Bosutinib
- Where
- 163 sites in United States, Australia and 14 more
- Volunteers
- 333 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Myeloid Leukemia (CML)
Asciminib Frontline Risk Adapted
This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD.
- Trial name
- ARTIST (NCT07804901)
- Testing
- Dasatinib 80mg QD (5 days per week), Standarc of Care
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Prof. Dr. med. Andreas Hochhaus
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be…
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
- Trial name
- NCT03459534
- Testing
- Radotinib HCl
- Where
- 18 sites in Russia, South Korea and 2 more
- Volunteers
- 173 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
GVHD, Hematopoietic Cell Transplantation (HCT)
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes
- Trial name
- NCT07302776
- Testing
- Tacrolimus, Early Tacrolimus Taper Strategy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Chronic Myeloid Leukemia (CML)
Study of CD38 and CD56 in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
- Trial name
- NCT07740603
- Testing
- cd 38 and cd 56
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Chronic Myeloid Leukemia (CML)
Second STOP After Pioglitazone Priming in CML Patients
Single-center study, prospective, phase II trial. The study objectives are : To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI…
- Trial name
- PIO2STOP (NCT02889003)
- Testing
- Pioglitazone + TKI
- Where
- 6 sites in France
- Volunteers
- 26 people
- Sponsor
- Versailles Hospital
Chronic Myeloid Leukemia (CML)
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation.
- Trial name
- ASC4TARGET (NCT06514534)
- Testing
- ABL001/Asciminib
- Where
- 6 sites in France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML) in
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
This study is testing a new way to treat people with a type of blood cancer called chronic myeloid leukemia (CML) in chronic phase.
- Trial name
- NCT07538401
- Testing
- No high risk mutation, High Risk Mutation
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Myeloproliferative Disease, Polycythemia Vera
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML).
- Conditions
- Myeloproliferative Disease, Polycythemia Vera, Thrombocythemia Essential, Myelofibrosis, Primary
- Trial name
- ENERGIA (NCT07518940)
- Testing
- Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Carmen Fava
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in…
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
- Trial name
- CML (NCT05304377)
- Testing
- ELVN-001
- Where
- 45 sites in United States, Australia and 12 more
- Volunteers
- 250 people
- Sponsor
- Enliven Therapeutics
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
- Trial name
- NCT03595917
- Testing
- ABL001, Dasatinib, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Marlise Luskin, MD
Chronic Myeloid Leukemia (CML)
Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
The primary objective of the study is to assess the impact of the organizational model of the hematology center on the quality of life of patients with CML estimated through standardized tools (EORTC QLQ-30, CML24) and through…
- Trial name
- NCT07165535
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- University of Milano Bicocca
Chronic Myeloid Leukemia (CML)
Identification of BCR::ABL1 Mutations by Digital PCR in CML
The goal of this study is to asses the ability of digital PCR (ddPCR) to detect actionable mutations in adult CML patients with failure of TKI therapy.
- Trial name
- DiP-in-CML (NCT07158294)
- Testing
- Peripheral blood withdrawal for BCR::ABL1 mutations testing
- Volunteers
- 150 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in…
- Conditions
- CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
- Trial name
- PEARL (NCT06409936)
- Testing
- Asciminib, Nilotinib
- Where
- 11 sites in Spain
- Volunteers
- 160 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
CML (Chronic Myelogenous Leukemia), Chronic Phase CML
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without…
- Trial name
- CML (NCT06787144)
- Testing
- ELVN-001
- Where
- 4 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Enliven Therapeutics
Chronic Myeloid Leukemia (CML)
Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myeloid neoplasm characterized by the overproduction of mature granulocytes . Cluster of differentiation 47 (CD47) is a membrane protein, which is over-expressed by virtually all cancers and…
- Trial name
- NCT06865443
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.